PRactice of VENTilation in COVID–19 patients (PRoVENT-COVID) – an observational study of invasively ventilated patients in the Netherlands

Noor Boers¹, Michela Botta¹, Anissa Tsonas¹, Anna Geke Algera¹, Janesh Pillay¹, Dave Dongelmans¹, Janneke Horn¹, Alexander Vlaar¹, Markus Hollmann², Lieuwe Bos¹, Frederique Paulus¹,³Ary Serpa Neto⁴, Marcus J. Schultz¹,⁵,⁶ for the PRoVENT–COVID collaborators

Amsterdam University Medical Centers, location ‘Academic Medical Center’, Amsterdam, The Netherlands:
¹Department of Intensive Care
²Department of Anesthesiology

Amsterdam University of Applied Sciences, Faculty of Health, Amsterdam, The Netherlands:
³ACHIEVE, Centre of Applied Research

Hospital Israelita Albert Einstein; São Paulo, Brazil:
⁴Department of Critical Care Medicine

Mahidol University, Bangkok, Thailand:
⁵Mahidol–Oxford Tropical Medicine Research Unit (MORU)

University of Oxford, Oxford, United Kingdom:
⁶Nuffield Department of Medicine

Correspondence:
Prof. M.J. Schultz, MD PhD
Department of Intensive Care
C3-423
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
Email: m.j.schultz@amsterdummc.nl
TABLE OF CONTENTS

1. INTRODUCTION AND RATIONALE ................................................................. 7
   1.1 The coronavirus disease 2019 ................................................................. 7
   1.2 Lung protective ventilation ................................................................. 7
   1.3 Need for an observational study on ventilator settings ....................... 7
2. OBJECTIVES AND HYPOTHESIS .............................................................. 9
   2.1 Objectives ............................................................................................ 9
   2.1.1 Primary objective ................................................................................. 9
   2.1.2 Secondary objective ............................................................................. 9
   2.2 Hypothesis ............................................................................................. 9
   2.2.1 Primary hypothesis ............................................................................. 9
   2.2.2 Secondary hypothesis ........................................................................... 9
3. STUDY DESIGN ......................................................................................... 10
4. STUDY POPULATION .................................................................................. 11
   4.1 Population (base) .................................................................................. 11
   4.2 Inclusion criteria ................................................................................... 11
   4.3 Exclusion criteria ................................................................................... 11
   4.4 Sample size calculation ....................................................................... 11
5. METHODS .................................................................................................. 12
   5.1 Study parameters/endpoints ................................................................ 12
   5.1.1 Main study parameters .................................................................... 12
   5.1.2 Secondary study parameters ............................................................ 12
   5.2 Randomisation, blinding and treatment allocation ................................ 12
   5.3 Study procedures ................................................................................. 12
   5.4 Data collection ....................................................................................... 13
   5.4.1 Demographic data ............................................................................ 13
   5.4.2 Data on day of intubation OR admission to ICU if transferred from another hospital with mechanical ventilation ................................................................................................................................. 13
   5.4.3 Repeated measures ........................................................................... 13
   5.5 Withdrawal of individual subjects ....................................................... 15
   5.6 Replacement of individual subjects after withdrawal .................... 15
   5.7 Follow-up of subjects withdrawn from treatment ............................ 15
   5.8 Premature termination of the study ..................................................... 15
6. SAFETY REPORTING ................................................................................ 16
   6.1 Temporary halt for reasons of subject safety ................................... 16
   6.2 Serious adverse events (SAEs) .............................................................. 16
   6.3 Follow-up of adverse events ............................................................... 16
   6.4 Data Safety Monitoring Board (DSMB) ............................................. 16
7. STATISTICAL ANALYSIS ......................................................................... 17
8. ETHICAL CONSIDERATIONS ................................................................... 19
   8.1 Regulation statement ........................................................................... 19
   8.2 Recruitment and consent .................................................................... 19
   8.3 Benefits and risks assessment, group relatedness ............................ 19
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKI</td>
<td>Acute Kidney Injury</td>
</tr>
<tr>
<td>APACHE</td>
<td>Acute Physiology And Chronic Health Evaluation</td>
</tr>
<tr>
<td>ARDS</td>
<td>Acute Respiratory Distress Syndrome</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus disease 2019</td>
</tr>
<tr>
<td>DP</td>
<td>Driving Pressure</td>
</tr>
<tr>
<td>ETCO₂</td>
<td>End-tidal Carbon Dioxide</td>
</tr>
<tr>
<td>FiO₂</td>
<td>Fraction of inspired Oxygen</td>
</tr>
<tr>
<td>HCO₃⁻</td>
<td>Bicarbonate</td>
</tr>
<tr>
<td>IBW</td>
<td>Ideal Body Weight</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive Care Unit</td>
</tr>
<tr>
<td>I:E ratio</td>
<td>Inspiratory : Expiratory ratio</td>
</tr>
<tr>
<td>NIV</td>
<td>Non-invasive ventilation</td>
</tr>
<tr>
<td>PMax</td>
<td>Maximum airway pressure</td>
</tr>
<tr>
<td>Peak</td>
<td>Peak pressure</td>
</tr>
<tr>
<td>Pplateau</td>
<td>Plateau pressure</td>
</tr>
<tr>
<td>PaO₂</td>
<td>Partial Arterial Pressure of Oxygen</td>
</tr>
<tr>
<td>PaCO₂</td>
<td>Partial Arterial Pressure of Carbon Dioxide</td>
</tr>
<tr>
<td>PBW</td>
<td>Predicted Body Weight</td>
</tr>
<tr>
<td>PEEP</td>
<td>Positive End–Expiratory Pressure</td>
</tr>
<tr>
<td>RR</td>
<td>Respiratory Rate</td>
</tr>
<tr>
<td>RRSET</td>
<td>Set Respiratory Rate</td>
</tr>
<tr>
<td>SaO₂</td>
<td>Saturation of Arterial Oxygen</td>
</tr>
<tr>
<td>SAPS</td>
<td>Simplified Acute Physiology Score</td>
</tr>
<tr>
<td>SARS–CoV–2</td>
<td>Severe acute respiratory coronavirus–2</td>
</tr>
<tr>
<td>SD</td>
<td>Standard Deviation</td>
</tr>
<tr>
<td>SOFA</td>
<td>Sequential Organ Failure Assessment Score</td>
</tr>
<tr>
<td>SpO₂</td>
<td>Saturation of peripheral Oxygen</td>
</tr>
<tr>
<td>VT</td>
<td>Tidal Volume</td>
</tr>
<tr>
<td>VILI</td>
<td>Ventilator induced lung injury</td>
</tr>
<tr>
<td>VTE</td>
<td>Expiratory tidal volume</td>
</tr>
</tbody>
</table>
SUMMARY

Rationale
The novel coronavirus disease (COVID–19) pandemic is rapidly expanding across the world, with over 60,000 new cases each day as of late March 2020. Healthcare workers are struggling to provide the best care for patients with proven or suspected COVID–19. Approaches for clinical care vary widely between and within countries and new insights are acquired rapidly. This includes the way invasive ventilation is applied.

Objective
To determine and compare invasive ventilation settings and parameters in COVID–19 patients in the Netherlands, and to determine associations with clinical outcomes.

Hypotheses
Invasive ventilation settings and parameters vary between intensive care units (ICUs) in hospitals in the Netherlands; certain ventilator settings have an independent association with duration of ventilation in COVID–19 patients.

Study design
National, multicenter, service review.

Study population
Invasively ventilated patients with proven or suspected COVID–19.

Methods
In every patient, granular ventilator settings and parameters are collected from start of invasive ventilation for up to 72 hours. Patients will be followed up until ICU and hospital discharge, and until day 90.

Study endpoints
Main ventilator settings (including tidal volume, airway pressures, oxygen fraction and respiratory rate) (primary) and parameters (blood gas results); use of rescue therapies (including prone positioning); use of sedatives, vasopressors and inotropes; daily cumulative fluid balances; development of kidney injury; ventilator–free days and alive at day 28 (VFD–28), duration of ICU and hospital stay, and ICU, hospital and 90–day mortality.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness
Retrospective collection of data regarding ventilation management and major clinical endpoints is without risk for the individual patient.
1. INTRODUCTION AND RATIONALE

1.1 The coronavirus disease 2019
Coronavirus disease 2019 (COVID–19) is a lower respiratory tract infection caused by the severe acute respiratory coronavirus–2 (SARS–CoV–2), of which the first outbreak was reported in Wuhan, China in the beginning of December, 2019. Since then, it has rapidly spread across the globe, with over 60.000 new cases each day as of late March 2020.

Although most people who are infected by SARS–CoV–2 only develop mild symptoms, an estimated 5% of reported cases are admitted to the intensive care unit (ICU) because of severe hypoxemia and dyspnoea [1]. The majority of these patients have shown to require invasive ventilation, and in this group, the mortality is considerable [2].

1.2 Lung protective ventilation
Although invasive ventilation can be a necessary supportive strategy in patients with respiratory failure, it also has the potential to worsen pre-existing lung injury or even initiate it [3]. ‘Ventilator-induced lung injury’ (VILI) is mainly due to overdistension of the lungs, and is associated with a longer duration of ventilation and a higher mortality [4]. Lung protective ventilation, featuring low tidal volume (VT), reduced inspiratory plateau pressure (P_{plateau}) [5] and low driving pressure (DP) [6] has been suggested to reduce the risk of mortality and is considered the standard of care ([7-10]. The benefit of high positive end–expiratory pressure (PEEP) remains uncertain, as does the use of recruitment maneuvers. There is evidence that high PEEP with recruitment maneuvers harms patients with ARDS [11]. It is highly uncertain whether high PEEP with recruitment maneuvers benefits COVID–19 patients.

1.3 Need for an observational study on ventilator settings
Due to the rapid spread of COVID–19, ICUs worldwide are being overloaded with patients requiring invasive ventilation and healthcare workers are struggling to provide the best care. Approaches in clinical care are already known to vary widely between countries and regions, including the way invasive ventilation is applied [12-15]. It is probable that these variances are amplified by a lack of consensus in treatment due to the novelty of COVID–19. Because invasive ventilation of itself has a strong potential to cause lung damage, these variances could be associated with a difference in patient–centered outcomes, like duration of ventilation and mortality.
Therefore, it is of the utmost importance to observe ventilation strategies that are currently being applied in the treatment of COVID–19 patients. To make haste in this time of crisis, we propose a national, observational, retrospective study that is focused on the inventory of ventilation parameters. This study will form an important first step in creating standard guidelines for invasive ventilation of COVID–19 patients. Implementation of standard guidelines could reduce mortality worldwide.
2. OBJECTIVES AND HYPOTHESIS

2.1 Objectives

2.1.1 Primary objective
To determine and compare invasive ventilation settings and parameters in COVID–19 patients in intensive care units (ICU) of hospitals in the Netherlands.

2.1.2 Secondary objective
To determine whether certain ventilation settings have an independent association with duration of ventilation.

2.2 Hypothesis

2.2.1 Primary hypothesis
There is substantial variation in ventilation practices in COVID–19 patients admitted to the ICU’s of hospitals in the Netherlands.

2.2.2 Secondary hypothesis
Certain ventilation settings impact duration of ventilation.
3. STUDY DESIGN
Multicenter, national, retrospective, observational study in COVID–19 patients with respiratory failure, requiring invasive ventilation in intensive care unit (ICU) settings in hospitals in the Netherlands.
4. STUDY POPULATION

4.1 Population (base)
The data of at least 1,000 consecutively invasively ventilated COVID–19 patients admitted to intensive care units (ICUs) of hospitals in the Netherlands. This study will not be restricted to the ‘formal’ ICUs, as patients may also receive invasive ventilation at other locations within the hospital during the COVID–19 pandemic.

4.2 Inclusion criteria
- COVID–19, confirmed with PCR and/or presence of typical abnormalities on chest computer tomography (CT)
- Suspected COVID–19 infection, with no exclusion of diagnosis
- Having received invasive ventilation

4.3 Exclusion criteria
- Age <18 years
- Already included in the same study in another hospital
- Having had received invasive ventilation > 24 hours in a non–participating hospital

4.4 Sample size calculation
No formal sample size calculation is needed. We expect to capture at least 1,000 patients, but will continue collecting data of new patients for at least 8 weeks.
5. METHODS

5.1 Study parameters/endpoints

5.1.1 Main study parameters

- Ventilation mode;
- Tidal volume set ($V_T$) (mL);
- Expiratory tidal volume (VTE);
- Positive end-expiratory pressure (PEEP) (cm H$_2$O);
- Maximum airway pressure ($P_{max}$) (cm H$_2$O) or plateau pressure ($P_{plateau}$) or peak pressure ($P_{peak}$) (cm H$_2$O);
- Level of pressure support above PEEP (cm H$_2$O);
- Inspired fraction of oxygen ($FiO_2$) (%);
- Set and measured respiratory rate (RR) (min$^{-1}$); and
- Inspiration to expiration ratio (I:E) (ratio).

5.1.2 Secondary study parameters

- Number of ventilation–free days and alive at day 28 (VFD–28);
- Duration of ventilation in survivors;
- Use of prone positioning;
- Use of recruitment maneuvers;
- Incidence of acute kidney injury (AKI);
- Duration of ICU stay;
- Duration of hospital stay;
- ICU mortality;
- Hospital mortality;
- 28-day mortality; and
- 90-day mortality.

5.2 Randomisation, blinding and treatment allocation

Not applicable.

5.3 Study procedures

Patients will be included by the attending clinician. Participating centers will be visited by researchers to collect data of included patients.
5.4 Data collection

5.4.1 Demographic data

- Age (age categories);
- Gender (male or female);
- Height (cm);
- Weight (kg);
- Medication (categories); and
- Comorbidities (categories).

5.4.2 Data on day of intubation OR admission to ICU if transferred from another hospital with mechanical ventilation

- Date of hospital admission;
- Date of ICU admission;
- Date and time of intubation (if possible, also in transferred patients);
- Transferred under ventilation (if applicable) (yes or no);
- Duration of ventilation in previous hospital (if applicable) (days);
- Use of non-invasive ventilation (NIV) before intubation (yes or no) and if so, duration (hours);
- Acute Physiology and Chronic Health (APACHE) II score or APACHE IV score, or Simplified Acute Physiology Score (SAPS) II;
- Sequential Organ Failure Scores (SOFA); and
- Plasma creatinine in 24 hours before admission/intubation (mmol/L)

5.4.3 Repeated measures

- Within one hour after initiation of ventilation OR within first hour of arrival when the patient has been intubated in another hospital, AND 3 times a day at fixed time points (8:00 AM, and 4:00 PM and 8:00 PM) for a following 3-day period:
  - Ventilation data
    - Ventilation mode;
    - Tidal volume set (VT) (mL);
    - Expiratory tidal volume (VTE);
    - Positive end-expiratory pressure (PEEP) (cm H₂O);
o Maximum airway pressure (P\textsubscript{\text{max}}) (cm H\textsubscript{2}O) or plateau pressure (P\textsubscript{\text{plateau}}) or peak pressure (P\textsubscript{\text{peak}}) (cm H\textsubscript{2}O);

o Level of pressure support above PEEP (cm H\textsubscript{2}O);

o Inspired fraction of oxygen (FiO\textsubscript{2}) (%);

o Set an measured respiratory rate (RR) (min\textsuperscript{-1});

o Inspiration to expiration ratio (I:E) (ratio);

o Saturation of peripheral oxygen (SpO\textsubscript{2}) (%); and

o End-tidal carbondioxide (ET\textsubscript{CO\textsubscript{2}}) (kPa).

- Arterial blood gas (ABG) analysis
  o pH;
  o Partial pressure of oxygen (PaO\textsubscript{2}) (kPa or mmHg);
  o Partial pressure of carbon dioxide (PaCO\textsubscript{2}) (kPa or mm Hg);
  o Bicarbonate (HCO\textsubscript{3}-) (mmol/L);
  o Arterial saturation of oxygen (SaO\textsubscript{2}) (%);
  o Arterial lactate levels (mmol/L);
  o FiO\textsubscript{2} (%) at time point of ABG; and
  o Position of patient in which ABG was taken.

- Hemodynamics
  o Mean arterial pressure (mmHg);
  o Heart rate (bpm);

  o 3 times a day at fixed time points (8:00 AM, and 4:00 PM and 8:00 PM) for a following 3-day period:
    - Received paralytic drugs within the previous 8 hours (yes or no).

  o Every day at 8:00 AM for 72–hour period after admission
    - Life status (alive or deceased);
    - Location (in ICU, hospital or other facility);
    - Intubation status;
    - Sequential Organ Failure Scores (SOFA);
    - Cumulative dose of sedatives (mg);
    - Cumulative dose of vasopressors (mg);
    - Cumulative fluid balance during last 24 hours (ml);
    - Amount of fluid administered during last 24 hours (ml);
    - Urine output (ml/hour); and
• Plasma creatinine (mmol/L).
• Prone position (yes or no), and if yes, time and duration (hours);
• ABG in supine position;
• Use of recruitment maneuver (yes or no);
• Undergoing veno–venous, veno–arterial or arterio–venous extracorporeal membrane oxygenation (ECMO) (yes or no);
• Pneumothorax (yes or no)

Follow-up

• Life status at day 7, day 28 and day 90;
• Alive (yes or no), and if not, the date of passing;
• Location (ICU, hospital, home);
• Intubated (yes or no), and if not, extubation date;
• Acute Kidney Injury (yes or no);
• Date of discharge from ICU; and
• Date of discharge from hospital.

5.5 Withdrawal of individual subjects
Not applicable.

5.6 Replacement of individual subjects after withdrawal
Not applicable.

5.7 Follow-up of subjects withdrawn from treatment
Not applicable.

5.8 Premature termination of the study
Not applicable.
6. SAFETY REPORTING

6.1 Temporary halt for reasons of subject safety
Not applicable.

6.2 Serious adverse events (SAEs)
Not applicable.

6.3 Follow-up of adverse events
Not applicable.

6.4 Data Safety Monitoring Board (DSMB)
Not applicable.
7. STATISTICAL ANALYSIS

Descriptive statistics will be used to describe the study population, and data are expressed in number and relative proportions for categorical variables and median (quartile 25% – quartile 75%) for continuous variables.

As the outcome of this study is urgently needed, data analysis will be done in two sequential steps. The first step includes an analysis of all patients admitted for invasive ventilation in one of the participating ICUs in the first four weeks after admission of the first COVID–19 patients, which was in all centers within the first weeks of March 2020. This part of the analysis focusses on ventilation practices in the first weeks of the pandemic in the Netherlands. This analysis may underestimate the effect of ventilation variables and parameters on outcomes, as many patients will not yet be weaned from the ventilator and remain admitted in the ICU. The second step includes an analysis of all COVID–19 patients admitted during the total 10 weeks PRoVENT COVID will enroll patients, with a complete follow up till day 90. This analysis will provide an answer to the question whether certain ventilator settings, variables and parameters are associated with patient–centered and other important outcomes.

All analyses will be performed using multilevel (patients nested in hospitals), mixed modelling with hospitals as random effect. Ventilatory variables and parameters will be compared among the groups, and absolute differences with the respective 95%–confidence interval (CI) will be calculated as the absolute difference from a mixed–effect linear model considering the hospitals as random effect to account for within–center clustering. Categorical variables will be compared as the risk difference from the same model.

Cumulative distribution plots will be used to demonstrate the cumulative distribution frequency of ventilation variables. Vertical dotted lines will represent the cut–off for each variable and the horizontal dotted lines the respective proportion of patients reaching each cut–off. Cut–offs to form matrices may use widely accepted values for each variable, specifically 8 mL/kg PBW for tidal volume, 10 cm H₂O for PEEP, 30 cm H₂O for plateau pressure, and 15 cm H₂O for ΔP.

Mixed–effect multivariable logistic or linear regression model will used to identify factors independently associated with major outcomes, like death and VFD–28. Subanalyses are planned to investigate differences in ventilation practice and outcomes in the following prespecified subgroups: women versus men, and patients categorized by the body mass index.
All analyses will be conducted in R v.3.60 and a p value < 0.05 will be considered statistically significant.
8. ETHICAL CONSIDERATIONS

8.1 Regulation statement
This study will be conducted according to the principles of the Declaration of Helsinki (revision Fortaleza, Brazil, October 2013).

8.2 Recruitment and consent
Since the proposed study concerns a service review, no research related interventions will take place. Therefore, no ethical concerns exist. As pseudo–anonymous data, which can no longer be attributed to a specific data subject will be used, there is no concern for informed consent.

8.3 Benefits and risks assessment, group relatedness
This study does not result in any risk or burdens to patients.

8.4 Compensation for injury
Not applicable.
9. ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION

9.1 Handling and storage of data and documents
Subject data will be stored in a pseudo-anonymized form, which means that relating the individual data to identifiable patients would require disproportional effort. Used data as written in the case report form will not contain any identifiable or relatable data. All handling of personal data will comply with the General Data Protection Regulation and the ‘Reuse of care data for the purpose of research’ standard of the AMC.

9.2 Monitoring and Quality Assurance
Not applicable.

9.3 Amendments
Not applicable.

9.4 Annual progress report
Not applicable.

9.5 Temporary halt and (prematurely) end of study report
Not applicable.

9.6 Public disclosure and publication policy
Not applicable.
10. REFERENCES


